Alnylam Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALNY Nasdaq 2834 http://www.alnylam.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alnylam Pharmaceuticals, Inc.

Alnylam Pharma Poised to Shoot Higher - Jul 1st, 2020 3:48 pm
FOCUS-From Parkinson's to peanut allergy, pandemic puts brakes on new drugs - Jul 1st, 2020 11:00 am
Alnylam Reports New 12-Month Interim Data From the ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria - Jun 30th, 2020 1:00 pm
New Pharma ETF Focuses on Testing and Treatment for Infectious Diseases--but Not Covid-19 - Jun 28th, 2020 8:51 pm
Alnylam to Host Seventh Annual "RNAi Roundtable" Webcast Series - Jun 18th, 2020 11:00 am
Alnylam to Webcast Presentation at Bank of America Securities 2020 Napa Biopharma Conference - Jun 17th, 2020 8:00 pm
Alnylam???s Share Price Rises YTD on Pipeline Developments - Jun 17th, 2020 1:50 pm
Alnylam Announces Publication of ENVISION Phase 3 Study Results for Givosiran in the New England Journal of Medicine - Jun 10th, 2020 9:07 pm
Alnylam Reports Positive Phase III Results on Lumasarin - Jun 8th, 2020 2:00 pm
Alnylam Reveals Solid Lumasiran Results; Analyst Says Dicerna Better Pick - Jun 8th, 2020 7:24 am
Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1 - Jun 7th, 2020 11:15 am
Alnylam Pharmaceuticals, Inc. (ALNY): Hedge Funds Are Getting Bullish - Jun 4th, 2020 7:54 pm
Alnylam Announces Recipients of Second Annual Advocacy for Impact Grants Program - Jun 2nd, 2020 12:00 pm
Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress - Jun 1st, 2020 11:00 am
Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA - May 27th, 2020 1:47 pm
Alnylam to Webcast Presentations at Upcoming June Investor Conferences - May 26th, 2020 8:00 pm
Edited Transcript of ALNY earnings conference call or presentation 6-May-20 12:30pm GMT - May 26th, 2020 11:00 am
Alnylam Announces U.S. Food and Drug Administration Has Granted Priority Review of the Lumasiran New Drug Application for the Treatment of Primary Hyperoxaluria Type 1 - May 26th, 2020 11:00 am
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year? - May 25th, 2020 3:30 pm
Alnylam Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO® (patisiran) at the European Academy of Neurology Virtual Congress 2020 - May 22nd, 2020 4:30 pm